Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

BHR Capital Believes These Tankers Are Due For A Big Rebound

Page 1 of 2

Michael Thompson’s BHR Capital has submitted its 13F with the U.S. Securities and Exchange Commission for the quarterly period ended March 31. The firm had a public equity portfolio value of $877.68 million at that time, a decrease from the $1.05 billion it contained at the end of 2014. According to the filing, the firm had stakes mainly in finance, energy, and transportation stocks, with public equity exposure of over 90% to those three industries. BHR Capital mainly utilizes a value-oriented investment strategy, targeting event-driven investment openings that include special situations and taking advantage of specific catalysts with the aim of unlocking value in a stock. The New York City-based hedge fund was founded in 2009 and is currently headed by Thompson. When we look at the fund’s top small-cap picks for the quarter, we see that Thompson continues to bet heavily on a rebound in the oil tanker industry, which has been hit particularly hard by the depressed oil prices that have crippled the shares of the many stocks in the energy industry. Thompson’s top small-cap picks, which we’ll study in this article, are Golar LNG Limited (USA) (NASDAQ:GLNG), Gramercy Property Trust Inc (NYSE:GPT), and Scorpio Tankers Inc. (NYSE:STNG).



Why are we interested in the 13F filings of a select group of hedge funds? We use these filings to determine the top 15 small-cap stocks held by these elite funds based on 16 years of research that showed their top small-cap picks are much more profitable than both their large-cap stocks and the broader market as a whole; yet investors have been stuck (until now) investing in all of a hedge fund’s stocks: the good, the bad, and the ugly. Why pay fees to invest in both the best and worst ideas of a particular hedge fund when you can simply mimic the best ideas of the best fund managers on your own? These top small-cap stocks beat the S&P 500 Total Return Index by an average of nearly one percentage point per month in our backtests, which were conducted over the period of 1999 to 2012. Even better, since the beginning of forward testing at the end of August 2012, the strategy worked just as our research predicted and then some, outperforming the market every year and returning 142% over the last 33 months, which is more than 84 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

The latest revealed that Thompson has upped his stake to 3.94 million shares of Golar LNG Limited (USA) (NASDAQ:GLNG), which have a market value of $131.03 million as of March 31. The small-cap stock is also Thompson’s top overall stock pick. While still down 4% over the past year, Thompson did well to remain bullish on the stock, which has had a big second quarter, lifting its year-to-date returns to 29%. Golar CEO Gary Smith revealed that they would be developing two or more projects with Rosneft, with the projects targeting Sakhalin and Venezuela. Golar LNG Limited (USA) (NASDAQ:GLNG) earned a total of $390 million from the sale of Eskimo to LNG Partners. It also generated a total of $207 million from the sale of 7.17 million Partners common units. The liquefied gas shipping company announced a dividend of $0.45 per share payable on June 26, representing a yield of 3.79%. The ex-dividend date is today. In terms of earnings per share for the first quarter, the company recorded a loss of $0.14, which missed analysts’ consensus estimate by $0.07. Nonetheless, the stock currently has an average recommendation of “Buy” and a price target of $56.29, suggesting remaining upside potential of nearly 20%. Out of the 730 actively reporting hedge funds that we currently monitor, a total of 35 had long positions in the stock. These included Christopher Pucillo‘s Solus Alternative Asset Management, Christopher A. Winham’s Tide Point Capital, and Malcolm Fairbairn’s Ascend Capital.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!